Venlafaxine With or Without Zolpidem in Treating Hot Flashes and Associated Sleep Disorders in Women With Breast Cancer OR at High Risk for Developing Breast Cancer

This study has been completed.
Sponsor:
Information provided by:
Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT00084669
First received: June 10, 2004
Last updated: April 27, 2010
Last verified: April 2010

June 10, 2004
April 27, 2010
May 2004
October 2007   (final data collection date for primary outcome measure)
Sleep improvement by biologic data and actigraphy data at the end of study treatment
Not Provided
Complete list of historical versions of study NCT00084669 on ClinicalTrials.gov Archive Site
Quality of life by BDI, QOLI, PSI, NCCTG symptom diary, PSQI, MOS SF-36 at the end of study treatment
Not Provided
Not Provided
Not Provided
 
Venlafaxine With or Without Zolpidem in Treating Hot Flashes and Associated Sleep Disorders in Women With Breast Cancer OR at High Risk for Developing Breast Cancer
Targeting Insomnia to Enhance Hot Flush Treatment in Women Receiving Therapy for Breast Cancer or Breast Cancer Risk-Reduction

RATIONALE: Venlafaxine may be effective in relieving hot flashes caused by hormone therapy. Giving venlafaxine with zolpidem (a sleeping pill) may improve sleep and quality of life in women who are receiving hormone therapy for treatment or prevention of breast cancer.

PURPOSE: This randomized clinical trial is studying giving venlafaxine together with zolpidem to see how well it works compared to venlafaxine alone in relieving hot flashes and associated sleep disorders in women who are receiving hormone therapy to treat or prevent breast cancer.

OBJECTIVES:

  • Compare the effect of venlafaxine or another serotonin-reuptake inhibitor with vs without zolpidem, in terms of sleep continuity, in women with breast cancer or at high risk for developing breast cancer who experience hot flushes and associated sleep disorders.
  • Compare quality of life in patients treated with these regimens.

OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are stratified by concurrent use of serotonin-reuptake inhibitors (SRI).

  • Stratum 1 (no concurrent SRI): Patients are randomized to 1 of 2 treatment arms.

    • Arm I: Patients receive oral venlafaxine once daily and oral zolpidem once daily for 5 weeks*.
    • Arm II: Patients receive oral venlafaxine once daily and oral placebo once daily for 5 weeks*.
  • Stratum 2 (concurrently on SRI): Patients are randomized to 1 of 2 treatment arms.

    • Arm I: Patients receive oral zolpidem once daily for 5 weeks*.
    • Arm II: Patients receive oral placebo once daily for 5 weeks*. NOTE: *After 5 weeks of study treatment, patients in stratum 1 may taper or continue venlafaxine over 2 weeks (for a total duration of venlafaxine use of 7 weeks); patients in arm I of both strata may taper or continue zolpidem over 1 week (for a total duration of zolpidem use of 6 weeks); continuation or tapering of drugs in both arms occurs in an open-label fashion off study.

In both strata, treatment continues in the absence of unacceptable toxicity.

In both strata, hot flushes, sleep continuity, sleep quality, and quality of life are assessed at baseline and at weeks 1, 3, and 6.

PROJECTED ACCRUAL: A total of 119 patients will be accrued for this study within 20 months.

Interventional
Not Provided
Allocation: Randomized
Masking: Double-Blind
Primary Purpose: Supportive Care
  • Breast Cancer
  • Hot Flashes
  • Sleep Disorders
  • Drug: venlafaxine
  • Drug: zolpidem tartrate
  • Procedure: management of therapy complications
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
119
March 2010
October 2007   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • At increased risk of developing breast cancer, meeting 1 of the following criteria:

    • Diagnosis of 1 of the following:

      • Ductal carcinoma in situ
      • Invasive breast cancer
      • Lobular carcinoma in situ
      • Atypical ductal or lobular hyperplasia
      • Lobular carcinoma
    • Candidate for breast cancer risk reduction for any of the following:

      • Predisposing mutation in a breast cancer susceptibility gene
      • Prior chest radiotherapy for Hodgkin's disease
      • Gail model score > 1.67% over 5 years
  • Experiencing daytime and nocturnal hot flushes at least 14 times per week within the past 2 weeks
  • Experiencing sleep disturbance, characterized by the presence of all of the following for ≥ 1 month:

    • ≥ 3 awakenings per night occurring ≥ 3 nights per week
    • Insomnia impedes daytime function
    • Hot flushes are the primary cause of insomnia (determined at baseline visit)
  • Hormone receptor status:

    • Not specified

PATIENT CHARACTERISTICS:

Age

  • 18 to 65

Sex

  • Female

Menopausal status

  • Not specified

Performance status

  • ECOG 0-1

Life expectancy

  • At least 6 months

Hematopoietic

  • Not specified

Hepatic

  • AST and ALT ≤ 2.5 times upper limit of normal (ULN)
  • Bilirubin ≤ 1.5 times ULN

Renal

  • Creatinine ≤ 1.5 times ULN

Cardiovascular

  • No clinically significant cardiac disease
  • No uncontrolled hypertension within the past 3 months, defined as the following:

    • Diastolic blood pressure > 95 mm Hg on > 1 occasion
    • Systolic blood pressure > 160 mm Hg on > 1 occasion

Pulmonary

  • No clinically significant respiratory disease

Psychiatric

  • Beck depression inventory score ≤ 15
  • No active panic or depressive disorder within the past month
  • No lifetime history of bipolar or psychotic disorder
  • No active substance-use disorders, including alcohol and benzodiazepines, within the past year
  • No suicidal or homicidal ideation
  • No hypomania or mania

Other

  • No prior adverse reaction to venlafaxine or zolpidem
  • None of the following sleep disorders within the past 6 months:

    • Sleep apnea
    • Narcolepsy
    • Periodic limb movement disturbance
  • No abuse or misuse of study medication
  • No daytime sedation that interferes with ability to function
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective barrier contraception during and for 1 month after study participation

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • Not specified

Chemotherapy

  • More than 3 months since prior chemotherapy
  • No concurrent chemotherapy

Endocrine therapy

  • More than 1 month since prior regular use (> 25% of the time) of oral, transdermal, or injection preparations of androgens, estrogens, or progestins

    • Vaginal suppositories and creams allowed
  • No concurrent regular use of oral, transdermal, or injection preparations of androgens, estrogens, or progestins

Radiotherapy

  • See Disease Characteristics
  • More than 3 months since prior radiotherapy
  • No concurrent radiotherapy

Surgery

  • See Disease Characteristics

Other

  • More than 1 month since prior regular use (> 25% of the time) of any of the following:

    • Hypnotic agents (e.g., benzodiazepines, zolpidem, zaleplon, trazodone, or diphenhydramine)
    • Clonidine
  • More than 1 month since prior antidepressants or other medications that are known to influence mood > 25% of the time (no serotonin-reuptake inhibitors [SRI] stratum only)
  • Concurrent SRI required provided they were initiated ≥ 1 month ago at or above the minimum dose, including any of the following (concurrent SRI stratum only):

    • Fluoxetine
    • Paroxetine
    • Paroxetine CR
    • Sertraline
    • Citalopram
    • S-citalopram
    • Venlafaxine
    • Fluvoxamine
  • No concurrent warfarin
  • No concurrent hypnotic agents, clonidine, or antidepressants, or other medications known to influence sleep, or mood
Female
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00084669
CDR0000365502, MGH-DFCI-02311, DFCI-02311
Not Provided
Hadine Joffe, MD, Massachusetts General Hospital
Massachusetts General Hospital
Not Provided
Study Chair: Hadine Joffe, MD, MSC Massachusetts General Hospital
Massachusetts General Hospital
April 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP